GT Biopharma, Inc. (GTBP) - Form 10-Q Summary
Business Context and Reporting Period
Company: GT Biopharma, Inc.
Reporting Period: Quarter and six months ended June 30, 2026.
Business Overview: A clinical-stage biopharmaceutical company developing immune-oncology products using proprietary Tri-specific Killer Engager (TriKE) and Dual Targeting TriKE platforms. The company has no approved products and generates no revenue.
Operational Status: Fully remote as of July 1, 2024. The company operates as a single reportable segment.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(7,351,000) | $(30,945,000) |
| Net Loss Attributable to Common Stockholders | $(7,961,000) | $(31,030,000) |
| Operating Expenses | $7,360,000 | $3,445,000 |
| Cash Used in Operating Activities | $(6,728,000) | $(5,216,000) |
| Cash Provided by Financing Activities | $4,877,000 | $6,493,000 |
| Cash and Cash Equivalents (End of Period) | $4,960,000 | $4,044,000 (Beginning of 2026 period) |
| Total Assets | $5,788,000 | $8,106,000 (Dec 31, 2025) |
| Working Capital | $3,569,000 | $5,787,000 (Dec 31, 2025) |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased significantly by approximately $23.6 million (76%) compared to the prior year period. This improvement is primarily due to the absence of a $28.7 million non-cash "Loss on initial recognition of Greenshoe Rights liability" recorded in the prior year.
- Operating Expenses: Total operating expenses increased by $3.9 million (114%) year-over-year. Selling, general, and administrative (SG&A) expenses rose by $3.8 million, driven by increased marketing, legal, and consulting fees. Research and development (R&D) expenses remained relatively flat.
- Liquidity: Cash and cash equivalents decreased by approximately $1.9 million during the six-month period, despite financing proceeds of $4.9 million, due to operating cash burn.
- Capital Structure: The company issued Series L convertible preferred stock and warrants, raising net proceeds of $4.3 million. Significant anti-dilution adjustments were made to warrant exercise prices, reducing them to a floor price of $0.454.
Outlook, Risks, and Contingencies
- Going Concern: The filing raises substantial doubt about the company's ability to continue as a going concern. Management states that existing cash resources are insufficient to fund operations for one year from the filing date without additional financing.
- Product Pipeline:
- GTB-3650: Phase 1 clinical trial for AML/MDS is ongoing with the first 4 cohorts enrolled.
- GTB-5550: Phase 1a/1b basket trial for solid tumors began in May 2026.
- GTB-3550: Development suspended to focus on second-generation camelid nanobody platforms.
- NASDAQ Compliance: The company received a second 180-day compliance period (until November 16, 2026) to regain compliance with the $1.00 minimum bid price requirement. Failure to comply could result in delisting.
- Legal Proceedings:
- Ohri Matter: Arbitration with former CFO resolved amicably.
- Z-One, LLC: Claims dismissed with prejudice, but plaintiff has filed a notice of appeal.
- Silberfein, DiPietro, and Werthman Trust: Settlement in principle reached; finalizing terms.
- Internal Controls: Disclosure controls and procedures were deemed ineffective due to a material weakness in accounting for complex financial transactions (specifically Greenshoe Rights), which has not been fully remediated.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of current cash ($4.96M) against the stated burn rate and the timeline for securing additional financing.
- NASDAQ Status: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement before November 16, 2026, to avoid delisting.
- Dilution Risk: Review the impact of the 57.5 million outstanding warrants and the recent anti-dilution adjustments on future share count.
- Legal Settlements: Confirm the final terms and costs of the pending settlements with Silberfein, DiPietro, and Werthman Trust.
- Internal Controls: Assess the progress of remediation efforts regarding the material weakness in financial reporting controls.